

Patients' experiences of a suppoRted self-manAGeMent pAThway In breast Cancer (PRAGMATIC): Quality of Life Results

Surrey and Sussex Cancer Alliance

M Teoh,¹ L Matthews,² S May,² I Solis-Trapala,³ M Kothari,¹ D Bloomfield,⁴ C Zammit, ⁴ D Betal,⁴ R Santos,¹ E Stewart,¹ J Finlay⁴, K Nicholson,⁴ D Elwell-Sutton,⁴ F McKinna,⁵ H Gage,⁶ S Bell, ⁵ V Jenkins² ¹ Ashford & St Peters NHS Foundation Trust, ²SHORE-C, Brighton & Sussex Medical School, ³ School of Medicine, Keele University, 4 University Hospitals Sussex NHS Foundation Trust, ⁴Surrey & Sussex Cancer Alliance, Royal Surrey NHS Foundation Trust, ⁴Surrey Health Economics Centre , University of Surrey

Background

The National Health Service (NHS) Long Term Plan for Cancer prioritises the implementation of Personalised Stratified Follow up and Supported Selfmanagement (SSM) in early breast cancer (EBC). PRAGMATIC evaluated the experiences of EBC patients entering SSM and the impact on quality of life (QoL) over a period of 12 months

Methods

- Three Surrey and Sussex clinical teams identified patients
- · Study introduced by team & expression of interest sent to SHORE-C
- SHORE-C received consent & managed assessments
- Teams provided patients' clinical details & treatment history
- Questionnaires completed at baseline, 3, 6, 9 and 12 months

Questionnaires

- FACT-B specific QoL tool for patients with BC¹
- EQ-5D-5L is a generic HRQoL tool²
- GSE measures general coping style³
- GHQ-12 screens for psychological morbidity ⁴
- PRRS measures degree of financial burden and caring responsibilities⁵

Results

- · Baseline characteristics shown in Table 1.
- 110 pts were recruited between Feb and Nov 2020; 99 completed 12 month assessments
- · 32% (35/110) had received chemotherapy

Quality of Life


- FACT –B mean scores were significantly worse for patients who had chemotherapy
- Mean differences between chemotherapy and no chemotherapy groups were 8.53 (95% CI: 3.42 to 13.64), 5.38 (95% CI: 0.17 to 10.58) and 8.00 (95% CI: 2.76 to 13.24) at 6, 9 & 12 months, respectively

Table 1: Participants	Chemotherapy (n=35)	No Chemotherapy (n=75)
Sex: Male Female	1 34	1 74
Age group (y): <50 50-70 >70	13 (37%) 20 (57%) 2 (6%)	6 (8%) 51 (68%) 18 (24%)
Partner: Yes	22 (63%)	51 (68%)
Employed: Yes	21 (60%)	32 (43%)
Grade: DCIS 1 or 2 3	0 12 (34%) 23 (66%)	9 (12%) 52 (69%) 14 (16%)
Surgery* BCS Mastectomy	24 (69%) 11 (11%)	64 (85%) 12 (16%)
Endocrine therapy: Yes	26 (74%)	60 (80%)
Co-morbidities ≥2	10 (29%)	32 (43%)

* 1 participant had left BCS and right mastectomy

GHQ-12 Results

- Scores of ≥4 on GHQ12 indicates probable psychological morbidity
- Odds of psychological morbidity 5.5 fold higher in those who had chemotherapy
- 10 patients (4 chemo; 6 no chemo) had persistently high levels of psychological morbidity for 12 months




GSE results

- There was no statistically significant decline from baseline in self efficacy (GSE scores) for either group (means 31.6 chemotherapy; 31.1 no chemotherapy)
- GSE scores and psychological morbidity had a significant effect on the mean FACT-B total score, showing QoL decline in patients with high levels of psychological morbidity

PRRS Results

- At baseline 48% (53/110) were employed
- 12/53 stopped employment during the 12
 months
- Chemotherapy patients had lower scores across 12 months

PRRS higher score = better



- · Contact with community services was relatively low
- 68.2% contacted breast care nurses by phone or email, 53.3% visited a hospital breast clinician

Conclusions:

Service Use

- EBC patients who received chemotherapy had lower QoL compared to those who did not have chemotherapy
- · QoL was significantly impacted by high levels of psychological morbidity
- · BC teams could consider screening for heightened anxiety/depression before

starting SSM to identify patients who may benefit from active interventions and/or

closer monitoring

- References 1. Brady MJ et al. J Clin Oncol. 1997; 15(3):974-86.
- 2. Herdman M et al. Qual Life Res. 20 (10): 1727-36
- 3. Schwarzer R, Jerusalem M 1995; A user's portfolio ed. Weinman & Johston 35-37
- 4. Goldberg & Williams. 1988; Windsor: nferNelson
- 5. Shilling et al. Qual Life Res 2018; 427(11):2923-2934

Study sponsored by University of Sussex; and funded by Surrey and Sussex Cancer Alliance M. Teoh is Co-Clinical Lead of Personalised Care and Support programme at Surrey and Sussex Cancer Alliance Corresponding author address: m.teoh@nhs.net